Russian government has extended the authorization for the biopharmaceutical company Promomed to produce in the country an analog of the popular diabetes drug Ozempik without the consent of the patent owner until the end of 2025. Original Ozempik is no longer supplied to Russia by the Danish manufacturer Novo Nordisk.